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The research topic “NSAIDs Pharmacogenomics” comprises eight articles to which more than 60 authors
contributed. The main aim of this research topic was to gather a collection of articles that would ﬁll relevant
gaps on the inﬂuence of genetic variation in genes involved in the pharmacokinetics of NSAIDs, drug
response, or the risk of developing NSAID-related adverse events.
Major NSAID-related adverse events continue to pose a profound challenge for individual and
public health. Major adverse events affect the gastrointestinal, renal, or cardiovascular systems, and
include hypersensitivity reactions that, on occasion, can be life-threatening. NSAID-related adverse
events are common, accounting for perhaps up to 30% of hospitalizations due to adverse drug
reactions (Pirmohamed et al., 2004).
Despite the extensive work carried out in this ﬁeld that has led, for instance, to the development of
the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and
NSAIDs (Theken et al., 2020). However, there are still many knowledge gaps including the potential
contribution of other CYP and non-CYP genes to the metabolism of NSAIDs, drug targets affecting
response, as well as the pharmacokinetics, therapeutic effects, and the risk of developing adverse
events with NSAIDs and other COX inhibitors.
Two articles in this research topic addressed gastrointestinal bleeding which is one of the most relevant
and life-threatening adverse effects of NSAIDs. McEvoy et al. reviewed genetic factors involved in NSAIDinduced gastrointestinal toxicity and concluded that CYP2C genetic variants are neither necessary nor
sufﬁcient to predispose to NSAID-induced peptic ulcer disease. However, low CYP2C9 activity may increase
gastrointestinal toxicity risk after the use of NSAIDs that are metabolized by CYP2C9. The authors also
highlight the potential role of the interaction between genetic factors and multimorbidity and polypharmacy.
Mallah et al. studied the contribution of gene variation to upper gastrointestinal hemorrhage in aspirin users.
In contrast to other NSAIDs, CYP metabolism only plays a minor role in aspirin biodisposition (Agundez
et al., 2009) and no strong genetic associations with aspirin-related gastrointestinal events have been
described so far. The authors analyzed 25 single nucleotide variants (SNVs) in genes involved in platelet
activation, angiogenesis, and inﬂammatory response. The strongest positive associations were related to
three intronic (SNVs) and therefore, these preliminary ﬁndings require further studies with larger sample
sizes and additional gene expression analyses.
Another major NSAID-related adverse event is hypersensitivity. Approximately two to four percent of
adults have reported at least one event of hypersensitivity to NSAIDs (Gomes et al., 2004; Zhou et al., 2016).
This, together with the wide consumption of these drugs without a prescription makes NSAID
hypersensitivity a major health challenge. Trinh et al. reviewed recent advances in NSAID
hypersensitivity, emphasizing the role of the arachidonic acid pathway in the development of these
reactions, the genetic variants involved in NSAID hypersensitivity, and the role of epigenetics. The authors
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conclude that the various clinical phenotypes and subphenotypes
observed in NSAID hypersensitivity are the consequence of
mechanisms regulated by genetic and epigenetic variants and
possible interactions between them, which could manifest
differently among populations. Jurado-Escobar et al. analyzed the
role of genetic variation in the cytosolic phospholipase A2 gene
(PLA2G4A), which is crucial in the bioavailability of arachidonic
acid. They identiﬁed three SNVs that were related to the risk of
developing NSAID-induced acute urticaria and angioedema. This
study adds to the potential role of variations in the genes encoding
drug targets, that is COX-1 and COX-2, in the development of adverse
events with NSAIDs (Garcia-Martin et al., 2021). Macías et al.
analyzed the potential impact of polymorphic CYP2C-mediated
NSAID metabolism in the risk of developing cross-hypersensitivity
to NSAIDs. The fact that cross-hypersensitivity is linked to COXinhibition, supports the hypothesis that individuals with impaired
NSAID biodisposition might be at an increased risk of developing this
adverse drug reaction. Common functional variants in CYP2C genes
were analyzed in a large cohort. The only statistically signiﬁcant
association identiﬁed was restricted to NSAIDs that are CYP2C8/9
substrates. Individuals who are homozygous for the CYP2C8*3 alleles
appeared to exhibit an increased risk of developing crosshypersensitivity. However, this association was not statistically
signiﬁcant after accounting for multiple comparisons, and the
study concluded that there is no evidence implicating the most
common functional CYP2C polymorphisms and the risk of
developing cross-hypersensitivity to NSAIDs.
Finally, two articles analyzed the role of genetic variation impacting
NSAID pharmacokinetics and pharmacodynamic effects. Mejía-Abril
et al. investigated the role of several functional variations in the genes
CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6,
CYP3A4, CYP3A5, ABCB1, ABCC2, SLCO1B1, SLC22A1, and
UGT1A1 on the pharmacokinetics of dexketoprofen. Although the
number of participants was small, the authors identiﬁed an association
between a synonymous ABCB1 variant, as well as weak associations
with CYP1A2, CYP2B6, and CYP2D6 and dexketoprofen exposure.

Overall, no major associations with the pharmacokinetics of
dexketoprofen were identiﬁed, however. Weckwerth et al. studied
the role of common variants in the OPRM1 and COMT genes, as well
as interleukin and interferon concentrations in saliva, on postoperative
pain in 200 individuals who received 600 ibuprofen. The study is based
on the hypothesis that polymorphisms in OPRM1 and COMT would
impact β-endorphin and catecholaminergic signaling, respectively,
which may result in differences in perception and modulation of pain
and analgesia. The study concluded that, among other factors, variants
in the COMT gene, and the concentrations of IL-2 and IFN-γ in saliva
before surgery were predictors for pain perception. While these
ﬁndings warrant replication, they may add to the well-established
role of genetic variation in ibuprofen biodisposition (and hence
effects), thus identifying additional factors that could impact
analgesic efﬁcacy.
The collection of articles included in the research topic “NSAIDs
Pharmacogenomics” highlights the importance of deep phenotyping
in studies addressing variation in drug action, since the mechanisms
underlying NSAID response seem to be multifactorial and
phenotype-dependent. The genetics of the response to NSAIDs
are more complex than one might expect for a drug class as
commonly consumed as this one, and the underlying mechanisms
and risk factors for NSAID-related adverse events appear to differ in
patients with different subphenotypes. Although the articles included
in this research topic shed light on key factors of NSAID
pharmacogenomics, additional research is needed to gain further
insights as we move toward improving the safety and efﬁcacy of
NSAIDs by precision therapy.
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